Prostacyclin/thromboxane ratio in human breast cancer.


In this prospective follow-up study the prognostic value of the tumor prostacyclin/thromboxane ratio in human breast carcinoma was investigated. The stable degradation products of prostacyclin and thromboxane (6-keto-PGF1 alpha and TXB2, respectively), were measured by radio-immunoassay in homogenized primary tumours from 29 patients with primary non… (More)


Cite this paper

@article{Vergote1991ProstacyclinthromboxaneRI, title={Prostacyclin/thromboxane ratio in human breast cancer.}, author={Ignace Vergote and P. A. van Dam and Gert M. Laekeman and G H Keersmaeckers and F. L. Uyttenbroeck and Anna Herman}, journal={Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine}, year={1991}, volume={12 5}, pages={261-6} }